Frontlight ResearchEarly access
Taking people in NetherlandsPhase 2
Testing ACT-1004-1239 against placebo in adults with progressive multiple sclerosis
Tests ACT-1004-1239 against placebo for nerve repair in adults with progressive multiple sclerosis.
Key facts
- Who runs it
- Idorsia Pharmaceuticals Ltd.
- Where
- Leiden, NetherlandsSee the site
- Trial code
- Registry title
- A trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 32 people, planned
- Started
- 3 Mar 2026
- Expected to end
- 24 Feb 2028
- Type of study
- Interventional
- Record updated
- 14 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 55 with primary or secondary progressive multiple sclerosis (MS) and no recent relapse.
- Age
- 18 to 55 years (the inclusion criteria say 18 to 55; the registry header lists a maximum age of 64).
- Sex
- Men and women can join.
- Disease stage
- Primary or secondary progressive MS, diagnosed by an MS-expert neurologist. EDSS score from 2.0 to 6.0. No clinical relapse in the 6 months before screening.
- Earlier treatment
- People already on a disease-modifying therapy must have been on a stable dose for at least 6 months before screening.
Main reasons for not taking part
- Cannot have MRI scans or lumbar punctures
- Other nerve or autoimmune disorders that could interfere with the trial
- Cancer in the last 5 years (with a few skin and cervical exceptions)
- Active infection or a major infection needing hospital or antibiotic treatment recently
- Pregnant, breastfeeding or planning pregnancy during the trial
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Male or female, aged ≥18 to ≤55 years
- Diagnosis of primary or secondary progressive MS according to the 2013 revisions of clinical course of MS and the 2017 revisions of the McDonald criteria by an MS- expert neurologist prior to Screening
- Absence of clinical relapse within 6 months prior to Screening
- Expanded disability status scale (EDSS) score ≥ 2.0 to ≤ 6.0
- If currently on disease-modifying therapy (DMT), it should be stable for ≥ 6 months prior to Screening
- For participants of childbearing potential: – Agreement to undertake monthly urine or serum pregnancy tests during the trial and up to 30 days after discontinuation of trial intervention – Agreement to use a highly effective method of contraception from Screening up to 30 days after discontinuation of trial intervention
Who cannot take part
- Active bacterial, viral, fungal, mycobacterial infection or any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks prior to Screening or with oral antibiotics within 2 weeks prior to Screening
- Not able or willing to stop treatment with moderate or strong CYP3A4 inhibitors or inducers from at least 4 weeks prior to randomization (i.e., at Visit 2)
- Receipt of a live (or live attenuated) vaccine within 6 weeks prior to randomization (i.e., 2 weeks prior to Visit 2)
- Known history or presence of other neurologic or systemic autoimmune disorders that are assessed by the investigator to potentially interfere with the collection of data or safety of the participant
- History of cancer within the last 5 years, including solid tumors and hematological malignancies (except basal cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of the cervix of the uterus that have been excised and resolved)
- Inability to comply with MRI scanning or undergo lumbar punctures
- Female participants: pregnant, lactating or planning to become pregnant during the trial (i.e., until 30 days after permanent discontinuation of trial intervention)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Centre for Human Drug ResearchLeiden, NetherlandsTaking people
About the trial
What the trial wants to find out
To evaluate the effect of ACT-1004-1239, compared with placebo, on remyelination in participants with progressive MS, as measured by magnetic resonance imaging (MRI)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A single-center, randomized, double blind, placebo-controlled, parallel-group, proof-of-concept trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis
- Plain-language title
- Testing ACT-1004-1239 against placebo in adults with progressive multiple sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-522922-11-00, who can take part
- Record updated
- 14 September 2026